个人简历
Education Experience 1994-1997 Ph. D. Medical Biochemistry UdS Medical School, Homburg, Germany 1997-2000 Postdoctoral Biochemistry Saarland University, Germany 1987-1994 Master of Science Chemistry Saarland University, Germany Professional Experience 2001-2004 Senior Scientist (C1) Department of Biochemistry, Saarland University, Germany 2004-2008 Senior Scientist (C2) Department of Biochemistry, Saarland University, Germany 2008-2012 CEO PomBioTech GmbH, Germany 2012-2014 Lecturer & Senior Scientist Department of Biochemistry, Saarland University, Germany
研究领域
The research in the Bureik group encompasses two primary areas: 1) The study of human drug metabolizing enzymes and their use for organic synthesis. A major goal in this project involves systematic testing of all variants of drug metabolizing cytochrome P450 enzymes (CYPs or P450s) and UDP glycosyltransferases (UGTs) identified in Chinese patients. This is expected to aid doctors in choosing the correct dosage for patients. 2) Investigation of human CYP4Z1 and exploitation of its activity for the treatment of breast cancer. In this project, we have successfully identified CYP4Z1 to catalyze fatty acid in-chain hydroxylase and also ether cleavage. A primary aim is to search for compounds that can act as CYP4Z1-activated prodrugs and have potential for treatment of breast cancer. Recently published work: In cooperation with the group of Prof. Gerhard Wolber (Free University Berlin, Germany) we recently published a homology model of a UGT1A5 variant (UGT1A5*8) which shows that the cofactor UDP-GA is placed in a much more favorable geometry in UGT1A5*8 as compared to the wild-type, thus explaining its increased catalytical activity (Yang et al., 2018):
近期论文
Fan, L., J.F. Joseph, P. Durairaj, M.K. Parr & M. Bureik (2019) Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1. Biol Chem. in press Cao, X., P. Durairaj, F. Yang & M. Bureik (2019) A Comprehensive Overview of Common Polymorphic Variants that Cause Missense Mutations in Human CYPs and UGTs. Biomed Pharmacother. 111: 983-992 Yang F, Machalz D, Wang S, Li Z, Wolber G, Bureik M (2018) A common polymorphic variant of UGT1A5 displays increased activity due to optimized cofactor binding. FEBS Lett 592: 1837-1846 Liu J, Chen L, Joseph JF, Nass A, Stoll A, de la Torre X, Botre F, Wolber G, Parr MK, Bureik M (2018) Combined chemical and biotechnological production of 20betaOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT). J Inorg Biochem 183: 165-171 Yan Q, Machalz D, Zollner A, Sorensen EJ, Wolber G, Bureik M (2017) Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast. Biochem Pharmacol 146: 174-187 Liu L, Pathak JL, Zhu YQ, Bureik M (2017) Comparison of cytochrome P450 expression in four different human osteoblast models. Biol Chem 398: 1327-1334 Yang X, Hutter M, Goh WW, Bureik M (2017) CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer. Curr Pharm Des 23: 2060-2064 Nunna V, Jalal N, Bureik M (2017) Anti-CYP4Z1 autoantibodies detected in breast cancer patients. Cell Mol Immunol 14, 572-574
